Abstracts tagged "interferons"

Abstract Number: 2097 • 2018 ACR/ARHP Annual Meeting
Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease Severity and Alters Immune Cell Subsets in the NZB/W F1 Murine Model of Lupus
Pei Han¹, Christopher Pohlmeyer¹, Ching Shang¹, Zhihua Cui², David Lopez³, Astrid Clarke², Randall Jones², Nevena Mollova³, Igor Mikaelian⁴, David Newstrom³, Shiva Zaboli³, Allyson Shauf³ and Julie Di Paolo⁵, ¹Immunology and Inflammation, Gilead Sciences, Foster City, CA, ²Gilead Sciences, Seattle, WA, ³Gilead Sciences, Foster City, CA, ⁴Biology Core Support, Gilead Sciences, Foster City, CA, ⁵Immunology and Inflammation Biology, Gilead Sciences, Inc., Foster City, CA
Background/Purpose: SLE is a heterogeneous autoimmune disease characterized by immune system hyper-activation leading to the production of autoantibodies and immune attack on multiple organs including…
Abstract Number: 2121 • 2018 ACR/ARHP Annual Meeting
Serum High Type I Interferon Is Associated with Active Proliferative Lupus Nephritis in Lupus Patients Accompanied with High Interferon Signature Gene Expression and Plasmacytoid Dendritic Cell Infiltration in Lupus Nephritis Kidney
Taro Iwamoto¹, Jessica M. Dorschner², Mark A. Jensen¹, Shanmugapriya Selvaraj³, Danielle Vsetecka², Shreyasee Amin², Ashima Makol², Floranne C. Ernste², Thomas Osborn², Kevin Moder², Vaidehi R. Chowdhary², Valeria Mezzano⁴, Peter M. Izmirly⁵, H. Michael Belmont⁵, Robert M. Clancy¹, Jill P. Buyon¹, Ming Wu³, Cynthia A. Loomis³ and Timothy B. Niewold¹, ¹Colton Center for Autoimmunity, New York University, New York, NY, ²Mayo Clinic College of Medicine, Rochester, MN, ³Department of Pathology, New York University, New York, NY, ⁴Division of Cardiology, New York University, New York, NY, ⁵Division of Rheumatology, New York University, New York, NY
Background/Purpose: Despite recent advancements in immunosuppressive therapies, lupus nephritis (LN) remains one of the most severe organ manifestations in systemic lupus erythematosus (SLE). High type…
Abstract Number: 2280 • 2018 ACR/ARHP Annual Meeting
Transcriptomic Analysis of Hidradenitis Suppurativa Skin Demonstrates Dysregulation of Antimicrobial Proteins and Inflammatory Pathways
Victoria Shanmugam¹, Derek Jones², Matthew Bendall³ and Keith Crandall⁴, ¹Rheumatology, The George Washington University, Washington, DC, ²The George Washington University, Washington, DC, ³Department of Microbiology, Immunology and Tropical Medicine, The George Washington University, Washington, DC, ⁴Department of Biology, The George Washington University, Washington, DC
Background/Purpose: Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory disease of the apocrine sweat glands. The purpose of the current study was to identify transcripts…
Abstract Number: 52 • 2018 ACR/ARHP Annual Meeting
Interferon-Alpha Protects Against Pain and Joint Damages in Experimental Arthritis and Is Associated with Expansion of Highly Suppressive Regulatory T Lymphocytes in Protected Mice and in Tocilizumab-Treated Rheumatoid Arthritis Patients
Matthieu Ribon¹, Roxane Hervé², Delphine Lemeiter², Katarzyna Matyja¹, François Santinon¹, Darragh Duffy³, Ken Tsumiyama⁴, Shunichi Shiozawa⁵, Marie-Christophe Boissier⁶, Natacha Bessis² and Patrice Decker¹, ¹Inserm UMR 1125, Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ²Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ³Institut Pasteur, Paris, Paris, France, ⁴Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan, ⁵Institute for Rheumatic Diseases, Nagahama, Japan, ⁶Rheumatology Department, AP-HP, Avicenne Hospital, Bobigny, France
Background/Purpose: Type I interferons (IFN-I) can be both anti- and pro-inflammatory. Among them, IFN-α inhibits normal Th17 differentiation, whereas it is pathogenic in lupus. The…
Abstract Number: 105 • 2018 ACR/ARHP Annual Meeting
Immunologic Properties of Cutaneous Lupus Erythematosus (CLE) Patients Refractory to Antimalarials Compared to Patients That Respond to Antimalarials
Majid Zeidi^1,2, Krisha Desai^3,4, Hee Joo Kim^3,4,5 and Victoria P. Werth^3,4, ¹University of Pennsylvania, Philadelphia, PA, ²Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ³Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Department of Dermatology, Gachon Gil Medical Center, School of Medicine, Gachon University, Incheon, Korea, Republic of (South)
Background/Purpose: Two major therapies for cutaneous lupus erythematosus (CLE) are the antimalarials, hydroxychloroquine (HCQ) and quinacrine (QC). HCQ is often the first-line therapy for CLE,…
Abstract Number: 125 • 2018 ACR/ARHP Annual Meeting
Monocyte Transcriptome Delineates SSc Patients with Functionally Distinct Patterns of Gene Dysregulation That Persist through Differentiation
Julia L.M. Dunn¹, Philip J. Homan², Salina Dominguez¹, Carla M. Cuda¹, Kathleen Aren³, Mary A. Carns^3,4, Tracy M. Frech⁵, Dinesh Khanna⁶, Shervin Assassi⁷, Harris Perlman¹, Monique Hinchcliff¹ and Deborah R. Winter¹, ¹Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Division of Rheumatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁴Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁶Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁷Rheumatology, University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: The etiology and pathogenesis of SSc are poorly understood; however, an increasing body of evidence supports an early inflammatory phase that precedes, and may…
Abstract Number: 878 • 2018 ACR/ARHP Annual Meeting
IFN Level Assessed By Ultrasensitive Detection Technology in Myositis Patient: A Promising Biomarker of Disease Activity in Dermatomyositis and Anti-Synthetase Syndrome
Loïs BOLKO^1,2, Ségolène Toquet³, Océane Landon-Cardinal⁴, Karim DORGHAM⁵, Celine Anquetil⁶, Darragh Duffy⁷, Nadège WESNER⁸, Damien Amelin⁹, Gaëlle DZANGUE TCHOUPOU², Perrine Guillaume¹⁰, Aude Rigolet¹¹, Baptiste Hervier¹¹, Mathieu Vautier¹¹, Nicolas Champtiaux¹¹, Guy Gorochov¹², Jean-Hugues Salmon¹³, Olivier Benveniste¹¹ and Yves Allenbach¹⁴, ¹Rheumatology, CHU Reims, Hôpital Maison Blanche, Reims, France, ²INSERM UMRS974, Pitié-Salpêtrière University Hospital, Paris, France, ³Médecine interne, CHU Reims, Robert debré, Reims, France, ⁴Rhumatologie, Hopital Notre-Dame Montréal, Montreal, QC, Canada, ⁵CIMI, INSERM, Paris, France, ⁶CDR en myologie UMR974,, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, PARIS, France, ⁷Institut Pasteur, Paris, Paris, France, ⁸INSERM UMRS974, Pitié-Salpêtrière University Hospital, paris, France, ⁹Sorbonne Universités UPMC Univ Paris 06, Myology research center, INSERM UMRS974, CNRS FRE3617, Pitié-Salpêtrière University Hospital, Paris, France, Paris, France, ¹⁰Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Universitaire Pitié Salpêtrière, paris, France, ¹¹Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ¹²CIMI, INSERM, paris, France, ¹³Service de Rhumatologie, CHU Reims, Hôpital Maison Blanche, Reims, France, ¹⁴Internal Medicine and Clinical Immunology, Sorbonne University - Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Inflammatory idiopathic myopathies (IIM) is a heterogeneous group of disorders ranging from muscle specific auto-immune diseases to systemic ones (dermatomyositis (DM), anti-synthetase syndrome (ASS),…
Abstract Number: 1080 • 2018 ACR/ARHP Annual Meeting
Hypomethylation of STAT1 and HLA-DRB1 in CD8+ T Cells Is Associated with Type-I Interferon-Dependent HLA-DRB1 Overexpression and Activation of Autologous CD4+ T Cells in Systemic Lupus Erythematosus
Shaylynn Miller¹, Patrick Coit¹, Elizabeth Gensterblum-Miller¹, Paul Renauer^1,2, Nathan Kilian^1,3, Mark Schonfeld¹, Pei-Suen Tsou¹ and Amr H Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Department of Genetics, Yale University, New Haven, CT, ³Medical School, Georgetown University, Washington, DC
Background/Purpose: Systemic lupus erythematosus is a chronic autoimmune disease characterized by epigenetic dysregulation, and increased autoantibody and type-I interferon (IFN) production. The goal of this…
Abstract Number: 1093 • 2018 ACR/ARHP Annual Meeting
Serologic Evidence Linking Epstein Barr Virus Reactivation, Heightened Interferon Pathway Activation and Increased Disease Activity in Patients with Systemic Lupus Erythematosus
Rebecca Wood¹, Lauren Guthridge¹, Carla J. Guthridge², Rebecka L. Bourn¹, Hua Chen¹, Wade DeJager¹, Susan R. Macwana¹, Stan Kamp¹, Rufei Lu^1,3, Cristina Arriens¹, Eliza Chakravarty¹, Katherine Thanou¹, Joan T. Merrill¹, Joel M. Guthridge^1,4 and Judith A. James^4,5, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is a clinically heterogeneous disease oftentimes characterized by a waxing and waning course. Mechanisms of SLE flare remain elusive. This study examined relationships…
Abstract Number: 1096 • 2018 ACR/ARHP Annual Meeting
Unexpected Association between Health-Related Quality of Life and the Blood Interferon Modular Transcriptional Signatures in Patients with Systemic Lupus Erythematosus
Laurent Chiche¹, julie seguier², stephanie gentile², stephane burtey², bertrand dussol², philippe halfon³, wahiba bidaut³, elisabeth jouve² and Noémie Jourde-Chiche⁴, ¹Internal medicine, Hopital europeen, Marseille, France, ²aphm, marseille, France, ³hopital europeen, marseille, France, ⁴Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France
Background/Purpose: SLE has important effects on health-related quality of life (HRQOL) and is not well correlated to disease activity. As most SLE patients in remission…
Abstract Number: 1111 • 2018 ACR/ARHP Annual Meeting
CBS004, a Novel Monoclonal Antibody Against Bdca-2 Inhibits TLR-Induced Activation of Human pDC in Vitro and In Vivo. a Novel Therapeutic Target for Systemic Sclerosis
Clarissa Corinaldesi¹, Yasser M El-Sherbiny², Gemma Migneco³, Rebecca Ross¹, Steve Holmes⁴, Clive McKimmie⁵ and Francesco Del Galdo¹, ¹Leeds Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom, ³Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom, ⁴Capella Biosciences, LTD, London, United Kingdom, ⁵Virus Host Interactions Team, Section of Infection and Immunity, University of Leeds, Leeds, United Kingdom
Background/Purpose: Human plasmacytoid dendritic cells (pDCs) have been implicated in the pathogenesis of Systemic Sclerosis (SSc) through their ability to infiltrate the skin and secrete…
Abstract Number: 1893 • 2017 ACR/ARHP Annual Meeting
Pharmacokinetics (PK), Pharmacodynamics (PD), and Proposed Dosing of Oral Janus Kinase (JAK)1 and JAK2 Inhibitor Baricitinib in Patients with IFN-Mediated Autoinflammatory Diseases (AIDs)
Hanna Kim¹, Kristina M. Brooks², Paul Wakim³, Mary Blake⁴, Stephen R. Brooks⁵, Gina A. Montealegre Sanchez⁶, Adriana Almeida de Jesus⁶, Yan Huang⁶, Wanxia Li Tsai⁷, Massimo G. Gadina⁴, Parag Kumar² and Raphaela Goldbach-Mansky⁶, ¹Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ²Clinical Pharmacokinetics Research Unit, Pharmacy Department, NIH Clinical Center, Bethesda, MD, ³Biostatistics and Clinical Epidemiology Service, NIH Clinical Center, Bethesda, MD, ⁴Translational Immunology Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, ⁵Biodata Mining and Discovery Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, ⁶Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ⁷Translational Immunology, Office of Science and Technology, NIAMS/NIH, Bethesda, MD
Background/Purpose: JAK inhibitors reduce IFN-signaling ex vivo. We evaluated the PK and PD of the oral JAK1 and JAK2 inhibitor, baricitinib, from data collected in…
Abstract Number: 2336 • 2017 ACR/ARHP Annual Meeting
Expression of Myxovirus-Resistance Protein a: A Possible Marker of Muscular Disease Activity in Juvenile Dermatomyositis
Sirisucha Soponkanaporn¹, Claire Deakin², Lucy Marshall², Cerise Johnson², Peter Schutz¹ and Lucy R Wedderburn², ¹Infection Inflammation and Rheumatology Section, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom, ²Infection, Immunity and Inflammation Programme, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) is a chronic autoimmune myopathy characterized by proximal muscle weakness and typical skin rashes. Type I interferon (IFN) gene expression in…
Abstract Number: 2568 • 2017 ACR/ARHP Annual Meeting
Prophylactic and Therapeutic Administration of a JAK1-Selective Inhibitor Blocks and Reverses Nephritis and Sialadenitis in NZB/W-F1 Mice
Rachel Twomey¹, Stuart Perper¹, Susan Westmoreland¹, Terry Melim¹, Soumya Mitra¹, Zheng Liu¹, Manuel Duval¹, Carolyn Cuff², Andrew Long¹, Anthony Slavin² and Stephen Clarke¹, ¹AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²Immunology Discovery, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Signaling of most cytokine receptors occurs through the JAK-STAT pathway. This is true of cytokines linked to the etiology of systemic lupus erythematosus (SLE)…
Abstract Number: 2589 • 2017 ACR/ARHP Annual Meeting
Functional and Mechanistic Characterization of Anifrolumab, a Fully Human Monoclonal Antibody Targeting the Interferon Alpha Receptor 1 for the Treatment of SLE
Gary P. Sims¹, Jeffrey Riggs², Richard Hanna¹, Bhargavi Rajan³, Jodi Karnell¹, Kamelia Zerrouki¹, Divya Sagar¹, Inna Vainshtein³, Erika Farmer⁴, Meina Liang³, Miguel A. Sanjuan¹ and Roland Kolbeck¹, ¹Respiratory, Inflammation and Autoimmunity (RIA), MedImmune, LLC, Gaithersburg, MD, ²Respiratory, Inflammation and Autoimmunity (RIA), MedImmune LLC, Gaithersburg, MD, ³MedImmune, LLC, Mountain View, CA, ⁴Analytical Sciences, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Increased type I interferon (IFN) activity is associated with the pathogenesis of SLE. Anifrolumab, a fully human immunoglobulin (Ig) G1 κ monoclonal antibody in clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].